News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
USD.AI Unleashes $13M for AI Funding with Revolutionary GPU-Backed Loans
BitcoinWorld·2025/08/14 16:01
Bitcoin World Disrupt 2025: Aaron Levie’s Masterclass in Enterprise Reinvention and AI Innovation
BitcoinWorld·2025/08/14 16:01
Jeffs’ Brands Crypto Treasury: A Revolutionary $75M AI-Powered Investment Strategy
BitcoinWorld·2025/08/14 16:00
Bitcoin Price Soars: An Unprecedented $119,000 Ascent
BitcoinWorld·2025/08/14 16:00
Google TeraWulf Deal: Unveiling a Strategic $3.7B Bitcoin Mining Investment
BitcoinWorld·2025/08/14 16:00
Bitcoin Price Soars: BTC Breaks Above $119,000 Mark
BitcoinWorld·2025/08/14 16:00
Crucial Ukraine Ceasefire Talks: Trump’s Bold Outlook on Peace Prospects
BitcoinWorld·2025/08/14 16:00
Fed Rate Cut: St. Louis Chief’s Unwavering Stance Against 50 Bp Reduction
BitcoinWorld·2025/08/14 16:00
What’s next for Bitcoin after hitting a new ATH at $124k? Check forecast
Coinjournal·2025/08/14 16:00
Google Play to Enforce Licensing Rules for Crypto Wallet Providers in US, EU and Beyond
Google Play is tightening oversight on cryptocurrency wallet providers, with a new policy requiring licensing and compliance with “industry standards” in more than 15 jurisdictions — including the United States and European Union.
DeFi Planet·2025/08/14 16:00
Flash
12:56
Spot Gold Drops $14 in Short-Term Spot gold has fallen $14 in the short term, declining over 1.00% during the day, currently reported at $4133.10 per ounce. (Jin Shi)
12:51
Vivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.This approval marks a key step forward for the clinical application of this innovative therapy, allowing the company to begin initial safety and feasibility assessments in humans. The Radiogel® technology is designed to enable precise radiation treatment within tumors and is expected to provide a new treatment option for cancer patients. The approved clinical study will collect essential data to lay the foundation for larger-scale clinical trials in the future.
12:51
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level.This positive safety data lays the foundation for further exploration of higher doses and demonstrates the potential of this therapy in terms of patient tolerability.
News